ongoing phase

AEGR Lays Off 25% Staff, INCY Discontinues Ruxolitinib Trials, ZBH Gets FDA Nod
www.nasdaq.com

The company's lead drug candidate is GEN-003, an immunotherapy for the treatment of genital herpes, which is under phase II development. Later in the first quarter of 2016, Genocea expects to report 12-month durability data from the ongoing phase II …

6
Like
Save
Genocea Reports Third Quarter 2015 Financial Results
www.businesswire.com

On October 7, 2015, Genocea reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes. At its best …

3
Like
Save
Genocea tanks as pneumococcal vaccine development temporarily suspended
www.thepharmaletter.com

"For the time being, we are removing the development of GEN-004 from our near-term plans to focus our resources on the ongoing Phase II program for GEN-003, our immunotherapy for genital herpes, for which we recently announced positive six-month …

9
Like
Save
Today's Watch List: General Motors Company (NYSE:GM), Genocea Biosciences, Inc …
www.benchmarkmonitor.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

4
Like
Save
3 Biotech Stocks Are Getting Crushed: Genocea Biosciences Inc(NASDAQ:GNCA …
www.wallstreetpoint.com

“For the time being, we are removing the development of GEN-004 from our near-term plans to focus our resources on the ongoing Phase 2 program for GEN-003, our immunotherapy for genital herpes, for which we recently announced positive six-month …

7
Like
Save
Genocea shares hit all-time low after pneumonia vaccine fails to meet trial goals
www.bizjournals.com

“For the time being, we are removing the development of GEN-004 from our near-term plans to focus our resources on the ongoing Phase 2 program for GEN-003, our immunotherapy for genital herpes … and on maximizing the potential of our preclinical …

8
Like
Save
Moving Stocks: Intermolecular, Inc. (NASDAQ:IMI), Emerson Electric Co. (NYSE …
www.benchmarkmonitor.com

Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

9
Like
Save
Genocea Bio's T cell vaccine candidate flunks mid-stage trial; shares down 30 …
seekingalpha.com

For the time being, we are removing the development of GEN-004 from our near-term plans to focus our resources on the ongoing Phase 2 program for GEN-003, our immunotherapy for genital herpes, for which we recently announced positive six-month …

9
Like
Save
Top Stories: Nivalis Therapeutics, Inc. (NASDAQ:NVLS), Itau Unibanco Holding …
www.stocktranscript.com

… Genocea Biosciences, Inc. (NASDAQ:GNCA), announced positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

6
Like
Save
Noteworthy Biotech Stocks to Watch for – Genocea Biosciences Inc (NASDAQ:GNCA …
investorwired.com

… T cell-directed vaccines and immunotherapies, reported positive results from a planned interim analysis of data collected six months after dosing from its ongoing Phase 2 dose optimization trial evaluating GEN-003 for the treatment of genital herpes.

6
Like
Save